摘要
目的观察罗格列酮对冠心病合并2型糖尿病患者血糖、血脂、超敏C-反应蛋白(hs-CRP)、组织型纤溶酶原激活物(t-PA)及纤溶酶原激活物抑制剂-1(PAI-1)水平的影响。方法将50例患者随机分为治疗组(n=24)和对照组(n=26),对照组给予常规治疗,治疗组在常规治疗的基础上加用罗格列酮4 mg/d,于治疗前及治疗12周时检测空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白A1c(HbA1c)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、hs-CRP、t-PA和PAI-1的含量。结果经过12周的治疗,在血糖方面,两组FPG、2hPG、HbA1c均较治疗前明显下降,差异有统计学意义(P<0.05或P<0.01),且治疗组各指标均小于对照组,差异有统计学意义(P<0.05);在血脂方面,两组TC、LDL-C均较治疗前明显下降,差异有统计学意义(P<0.05),而除此之外,HDL-C显著上升,差异有统计学意义(P<0.05);在抗炎方面,两组hs-CRP均较治疗前明显下降,差异有统计学意义(P<0.05或P<0.01),且治疗组各指标均小于对照组,差异有统计学意义(P<0.05);在对纤溶系统的影响方面,治疗组t-PA明显上升、PAI-1显著下降,差异有统计学意义(P<0.05)。结论对于冠心病合并2型糖尿病患者,在常规治疗的基础上加用罗格列酮可更好地控制血糖,调节血脂和抗炎并改善体内血栓前状态。
[Objective]To observe the effect of rosiglitazone on levels of blood glucose,blood lipid,high-sensitivity C-reactive protein（hs-CRP）,tissue plasminogen activator（t-PA） and plasminogen activator inhibitor 1（PAI 1） in coronary heart diseases patient complicated with type 2diabetes mellitus. [Methods]50 patients were randomly divided into the treatment group（n=24） and the control group（n=26）.The control group was treated with routine therapy,and the treatment group was given rosiglitazone 4mg/d on the basis of routine therapy.The levels of FPG,2hPG,HbA1c,TG,TC,LDL-C,HDL-C,hs-CRP,t-PA and PAI 1 of both groups were tested before treatment and after 12 weeks of treatment. [Results]After 12 weeks of treatment,the levels of FPG,2hPG and HbA1c of both groups decreased significantly as compared with those before treatment（P0.05 or P0.01）,and all indexes of the treatment group were lower than those of control group（P0.05）.The blood lipid indexes showed： the levels of TC and LDL-C of both groups decreased significantly after treatment as compared with those before treatment（P0.05）,and the level of HDL-C increased significantly（P0.05）.The anti-inflammatory indexes showed： the levels of hs-CRP of both groups decreased significantly as compared with those before treatment（P0.05 or P0.01）,and all indexes of the treatment group were lower than those of control group（P0.05）.The fibrinolytic system indexes showed： in the treatment group,the level of t-PA increased and the level of PAI 1decreased,and the differences were significant（P0.05）. [Conclusion]On the basis of routine therapy,rosiglitazone can effectively control blood glucose level,regulate blood lipid level,play a role in anti-inflammatory and improve the pre-thrombotic state in coronary heart diseases patient complicated with type 2 diabetes mellitus.
出处
《职业与健康》
CAS
2011年第19期2269-2271,共3页
Occupation and Health
